Evidence map›Paper›PMID 38396896›Full record

ArticleInternational journal of molecular sciences2024

Assessment of the Impact of Carvedilol Administered Together with Dexrazoxan and Doxorubicin on Liver Structure and Function, Iron Metabolism, and Myocardial Redox System in Rats.

Jaroslaw Szponar, Agnieszka Gorska, Marta Ostrowska-Lesko, Agnieszka Korga-Plewko, Michal Tchorz, Erwin Ciechanski, Anna Dabrowska, Ewa Poleszak, Franciszek Burdan, Jaroslaw Dudka and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Jaroslaw SzponarToxicology Clinic, Faculty of Medicine, Medical University of Lublin, 100 Krasnik Avenue, 20-550 Lublin, Poland.
Agnieszka GorskaToxicology Clinic, Faculty of Medicine, Medical University of Lublin, 100 Krasnik Avenue, 20-550 Lublin, Poland.
Marta Ostrowska-LeskoDepartment of Toxicology, Medical University of Lublin, 8b Jaczewski Street, 20-090 Lublin, Poland.ORCID 0000-0002-3375-3821
Agnieszka Korga-PlewkoIndependent Medical Biology Unit, Medical University, 8b Jaczewski Street, 20-090 Lublin, Poland.ORCID 0000-0002-2027-9681
Michal TchorzToxicology Clinic, Faculty of Medicine, Medical University of Lublin, 100 Krasnik Avenue, 20-550 Lublin, Poland.
Erwin CiechanskiDepartment of Toxicology, Medical University of Lublin, 8b Jaczewski Street, 20-090 Lublin, Poland.ORCID 0000-0003-0058-896X
Anna DabrowskaDepartment of Toxicology, Medical University of Lublin, 8b Jaczewski Street, 20-090 Lublin, Poland.ORCID 0000-0001-7905-2871
Ewa PoleszakDepartment of Applied Pharmacy, Medical University of Lublin, 1 Chodźko Street, 20-093 Lublin, Poland.ORCID 0000-0003-4359-3953
Franciszek BurdanHuman Anatomy Department, Medical University of Lublin, 4 Jaczewski Street, 20-090 Lublin, Poland.
Jaroslaw DudkaDepartment of Toxicology, Medical University of Lublin, 8b Jaczewski Street, 20-090 Lublin, Poland.
Marek MuriasDepartment of Toxicology, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-608 Poznan, Poland.ORCID 0000-0002-2903-4912
Slawomir MandziukDepartment of Pneumology, Oncology and Allergology, Medical University of Lublin, 8 Jaczewski Street, 20-090 Lublin, Poland.
Medical University of Lublin · PLPoznan University of Medical Sciences · PL

Funding

Medical University of Lublin DS38
6 · The paper itself

Abstract

Late cardiotoxicity is a formidable challenge in anthracycline-based anticancer treatments. Previous research hypothesized that co-administration of carvedilol (CVD) and dexrazoxane (DEX) might provide superior protection against doxorubicin (DOX)-induced cardiotoxicity compared to DEX alone. However, the anticipated benefits were not substantiated by the findings. This study focuses on investigating the impact of CVD on myocardial redox system parameters in rats treated with DOX + DEX, examining its influence on overall toxicity and iron metabolism. Additionally, considering the previously observed DOX-induced ascites, a seldom-discussed condition, the study explores the potential involvement of the liver in ascites development. Compounds were administered weekly for ten weeks, with a specific emphasis on comparing parameter changes between DOX + DEX + CVD and DOX + DEX groups. Evaluation included alterations in body weight, feed and water consumption, and analysis of NADPH

Indexed as

AscitesCardiotoxicityAnimalsAntibiotics, AntineoplasticBody WeightCarvedilolDoxorubicinIronLipid PeroxidationLiverMyocardiumNADPRatsTransferrinAntibiotics, AntineoplasticCarvedilolDoxorubicinIronNADPTransferrincardiac molecular metabolismcardioprotectioncarvediloldexrazoxanedoxorubicinpost-anthracycline cardiotoxicity

Identifiers

PMID38396896
PMCPMC10889540
OpenAlexW4391781284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.